{"name":"Centocor Ortho Biotech Services, L.L.C.","slug":"centocor-ortho-biotech-services-l-l-c","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"infliximab infusion; AZA placebo caps","genericName":"infliximab infusion; AZA placebo caps","slug":"infliximab-infusion-aza-placebo-caps","indication":"Rheumatoid arthritis","status":"phase_3"}]}],"pipeline":[{"name":"infliximab infusion; AZA placebo caps","genericName":"infliximab infusion; AZA placebo caps","slug":"infliximab-infusion-aza-placebo-caps","phase":"phase_3","mechanism":"Infliximab is a chimeric monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and thereby inhibiting the inflammatory response.","indications":["Rheumatoid arthritis","Crohn's disease","Ulcerative colitis","Psoriatic arthritis","Ankylosing spondylitis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNUTV1Y01LeWhIbDNjMzdiSFg3WWJTelZydUdVMGFXTUFZN0VrTW16bFdkSks2d0xlU0tiN21lTGxMQkpxeGJrcXl0d244ZjRoN05ITXI1a2lWOV9KVUhTQlBiMVpLU1RoaVlWa2ZPWWVGRkRQSkpUZnBUZUJOLTdpaUtGb3cyQ3ZDWmhHWWE5UTI1dExlR2c?oc=5","date":"2023-10-25","type":"pipeline","source":"NewZimbabwe.com","summary":"US-based firm appoints Dr Victor Moyo as Chief Medical Officer - NewZimbabwe.com","headline":"US-based firm appoints Dr Victor Moyo as Chief Medical Officer","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}